Lubrication

Global Diabetes Care Devices Market Analysis/Forecasts Report 2022: A $42 Billion Market by 2028 - Rapid Technological Advancements in Diabetes Care Devices - ResearchAndMarkets.com

Retrieved on: 
Friday, September 23, 2022

However, the high cost of diabetes care devices is hampering the global diabetes care devices market growth

Key Points: 
  • However, the high cost of diabetes care devices is hampering the global diabetes care devices market growth
    Technological advancements in the healthcare industry are encouraging market players to focus on research and development of insulin delivery devices.
  • The continuous research in insulin pens supports the growth of the global diabetes care devices market during the forecast period.
  • The diabetes care devices allow diabetes patients to monitor and manage their diabetes in their homes.
  • The prevalence of type 1 diabetes patients is likely to fuel the demand for diabetes care devices.

The Malaysian and Vietnamese Air Compressor Industry is Expected to Reach $378 Million by 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 22, 2022

The Malaysia and Vietnam Air Compressor Market was valued at USD 227.2 million in 2021 and is predicted to reach USD 378.6 million by 2030 with a CAGR of 5.9% from 2022-2030.

Key Points: 
  • The Malaysia and Vietnam Air Compressor Market was valued at USD 227.2 million in 2021 and is predicted to reach USD 378.6 million by 2030 with a CAGR of 5.9% from 2022-2030.
  • Air compressors are used to compress the air by forcing more and more air into a storage tank, increasing its pressure.
  • Also, air compressors are widely used in medical equipment, vacuum packaging, spray painting, dehydrating, tool powering, and air blowing.
  • As air compressors are widely used in manufacturing industry, it is expected that these countries would witness significant growth in the air compressor market size due to the migration of these multinational companies.

Parker Aerospace Engine-Driven Pump Selected by Boeing to Power the B-52H Stratofortress Hydraulic System for Decades

Retrieved on: 
Tuesday, September 20, 2022

Parker Aerospace , a business segment of Parker Hannifin Corporation, the global leader in motion and control technologies, today announced that Boeing selected Parker to supply its AP15V engine-driven pump (EDP) for the hydraulic system of the B-52H Stratofortress.

Key Points: 
  • Parker Aerospace , a business segment of Parker Hannifin Corporation, the global leader in motion and control technologies, today announced that Boeing selected Parker to supply its AP15V engine-driven pump (EDP) for the hydraulic system of the B-52H Stratofortress.
  • The Parker AP15V EDP, also known as the World Pump, will help power the aircrafts hydraulic system through the 2050s.
  • View the full release here: https://www.businesswire.com/news/home/20220919005191/en/
    Parker Aerospaces AP15V World Pump has been selected for the B-52 Stratofortress hydraulic system, helping the aircraft meet fuel efficiency and reliability goals for the Commercial Engine Replacement Program (CERP).
  • Parker Aerospace looks forward to supporting Rolls-Royce and Boeing in achieving these objectives and maximizing aircraft readiness.

All-Electric Automaker Fisker has Standardized on GT-SUITE Simulations for Thermal Systems Engineering

Retrieved on: 
Monday, September 19, 2022

WESTMONT, Ill., Sept. 19, 2022 /PRNewswire-PRWeb/ -- Gamma Technologies (GT), a global leader and innovator in multi-physics system simulation software, is pleased to announce innovative electric automaker Fisker Inc. is our latest customer to standardize on GT-SUITE thermal simulations for design and optimization of their electric vehicles.

Key Points: 
  • is our latest customer to standardize on GT-SUITE thermal simulations for design and optimization of their electric vehicles.
  • For Fisker, GT-SUITE integrates all thermal systems into a single model that optimizes key vehicle attributes.
  • "To see companies like Fisker, who are fully committed to the next generation of engineering mobility, standardize on GT-SUITE's thermal management solutions is gratifying."
  • GT-SUITE includes a complete library of physics-based modeling templates covering fluid flow, thermal systems, mechanics, electrics, magnetics, chemistry, and controls.

Venture Into the Outdoors with Confidence - Equipment and Vehicle Prep Tips for Fall Hunting Season

Retrieved on: 
Wednesday, September 14, 2022

INDIANAPOLIS, Sept. 14, 2022 /PRNewswire/ -- It's open season on game around the country, and while all states have different types of wildlife, regulations and season dates, all hunters should take the time to prepare their equipment before heading into the wilderness. Skipping this step can cause misfires, missed opportunities, frustration, and in extreme cases, leave a hunter stranded in a dangerous situation. To avoid these issues, a little preparation and seasonal upkeep with the help of Lucas Oil products can help make equipment more reliable, safer and protected from harsh elements.

Key Points: 
  • Outdoor enthusiasts at Lucas Oil offer advice on essential prep and products to make the most of the season.
  • To hunt legally requires a hunting license, which can be purchased at most outdoor retailers that sell hunting and fishing equipment.
  • It also neutralizes acids from fingerprints and resists drying for long-term storage after hunting season ends.
  • "The fall hunting season is an excellent time to venture outdoors.

Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones

Retrieved on: 
Wednesday, September 14, 2022

In addition to the planned NDA submission for reproxalap in dry eye disease, Aldeyra highlighted the following expected upcoming corporate milestones:

Key Points: 
  • In addition to the planned NDA submission for reproxalap in dry eye disease, Aldeyra highlighted the following expected upcoming corporate milestones:
    The pre-NDA meeting for ADX-2191 for the treatment of primary vitreoretinal lymphoma has been scheduled for the fourth quarter of 2022.
  • Results from the Phase 2 clinical trial of ADX-2191 in retinitis pigmentosa are expected in the first half of 2023.
  • Among many physicians and patients, existing therapy for dry eye disease is generally regarded as inadequate and often requires weeks or months to demonstrate activity.
  • Expression of Lipid Peroxidation Markers in the Tear Film and Ocular Surface of Patients with Non-Sjogren Syndrome: Potential Biomarkers for Dry Eye Disease.

InvestmentPitch Media Video Discusses LOVE Pharma’s Strategic Investment in Starton Therapeutics, a New Jersey Based Clinical Stage Biotechnology Company

Retrieved on: 
Thursday, September 8, 2022

VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0), an international sexual health and wellness company, has made a strategic investment in Starton Therapeutics Inc., a New Jersey based clinical stage biotechnology company focused on transforming standard of care therapies in oncology.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0), an international sexual health and wellness company, has made a strategic investment in Starton Therapeutics Inc., a New Jersey based clinical stage biotechnology company focused on transforming standard of care therapies in oncology.
  • A Media Snippet accompanying this announcement is available by clicking on the image or link below:
    For more information, please view the InvestmentPitch Media video, which provides additional information about this news and the company.
  • If these links are not enabled, please visit www.InvestmentPitch.com and enter Love Pharma in the search box.
  • The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

ROCCAT Reveals the First Mini PC Gaming Keyboard in Its Award-Winning Vulcan Series With the Vulcan II Mini

Retrieved on: 
Tuesday, August 30, 2022

ROCCAT , Turtle Beachs (Nasdaq: HEAR) award-winning PC gaming peripherals brand, today revealed the all-new Vulcan II Mini Optical-Mechanical PC Gaming Keyboard.

Key Points: 
  • ROCCAT , Turtle Beachs (Nasdaq: HEAR) award-winning PC gaming peripherals brand, today revealed the all-new Vulcan II Mini Optical-Mechanical PC Gaming Keyboard.
  • View the full release here: https://www.businesswire.com/news/home/20220830005425/en/
    ROCCAT Reveals the First Mini PC Gaming Keyboard in its Award-Winning Vulcan Series With The Vulcan II Mini (Photo: Business Wire)
    The Vulcan II Mini is the worlds first keyboard with Dual LED Smart Key technology.
  • Additionally, the Vulcan II Mini features ROCCATs new TITAN II Optical Switches, an evolution of the brands original, fan-favorite optical switch.
  • I believe the Vulcan II Mini will set a new standard for what gamers should expect in smaller mini PC gaming keyboards moving forward.

InvestmentPitch Media Video Discusses LOVE Pharma’s Shareholders’ Letter from CEO Zach Stadnyk

Retrieved on: 
Friday, August 26, 2022

Zach Stadnyk, CEO, stated: We welcome this opportunity to provide our shareholders with a comprehensive picture of Love's efforts in building upon its existing portfolio and establishing its future strategic imperatives.

Key Points: 
  • Zach Stadnyk, CEO, stated: We welcome this opportunity to provide our shareholders with a comprehensive picture of Love's efforts in building upon its existing portfolio and establishing its future strategic imperatives.
  • A Media Snippet accompanying this announcement is available by clicking on the image or link below:
    For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company.
  • If these links are not enabled, please visit www.InvestmentPitch.com and enter Love Pharma in the search box.
  • For more information, please visit the companys website www.love-pharma.com, contact Zach Stadnyk, CEO, at 604-343-2977 or by email at [email protected].

Freya Pharma Solutions Announced Further Strengthening of its IP Position for Improved Treatment for Women Suffering From FSIAD

Retrieved on: 
Thursday, August 25, 2022

Last year Freya, Pharma Solutions acquired all Intellectual Property (IP) on 2 innovative drugs, Lybrido and Lybridos, developed for the treatment of women suffering from FSIAD.

Key Points: 
  • Last year Freya, Pharma Solutions acquired all Intellectual Property (IP) on 2 innovative drugs, Lybrido and Lybridos, developed for the treatment of women suffering from FSIAD.
  • Freya Pharma Solutions plans to conduct a pivotal phase 3 clinical trial to confirm the efficacy and safety of Lybrido in women suffering from FSIAD.
  • With the new patent applications Freya will further strengthen its IP position and provide strong protection for effective and safe treatment for women suffering from FSIAD."
  • Freya Pharma Solutions is a late clinical stage company focused on developing effective pharmaceutical therapies for FSIAD, building upon fifteen years of solid research.